Orum Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Orum Therapeutics is a biotechnology company focused on targeted protein degradation, pursuing a novel class known as degrader-antibody conjugates. These therapeutics combine antibody precision with specialized degrader payloads to drive the selective breakdown of disease-causing proteins within specific cells. By addressing proteins previously considered undruggable, Orum aims to expand the reach and potential safety of this therapeutic approach in clinical contexts. Its lead programs target GSPT1, and the company is developing next-generation payloads and proprietary linker technologies to broaden and refine its DAC pipeline.

Headquartered in Lexington, Massachusetts, with a presence in Daejeon, South Korea, Orum positions itself as a globally oriented biotech research company focused on cancer therapies for hard-to-treat diseases. It describes itself as a mid-sized firm in the life sciences sector and has recently expanded its governance, appointing Maria Koehler and Geoff Meyerson to its Board in April 2026. In March 2026, Orum participated in the AACR Annual Meeting to share preclinical data on ORM-1153, a CD123-targeting Degrader Antibody Conjugate, illustrating ongoing advancement of its DAC platform.

Sign up for free to view info

Email Format Employee directory